DBV Technologies is a clinical-stage biopharmaceutical company with no approved products or revenue. Its entire business centers on the Viaskin Peanut Patch, a daily-wear adhesive patch that delivers microgram-level doses of peanut protein to immune cells in the skin — without entering the bloodstream — to desensitize peanut-allergic children to accidental exposures. DBV is pursuing FDA approval for two age groups: children ages 4–7, supported by the Phase 3 VITESSE trial, with a BLA submission planned for the first half of 2026; and toddlers ages 1–3, supported by the Phase 3 EPITOPE trial, with a BLA submission targeted for the second half of 2026 under Accelerated Approval. If approved, DBV plans to commercialize the patch itself in the U.S., targeting roughly 670,000 peanut-allergic children ages 1–7 through a specialty sales force focused on allergists. Revenue would depend on physician adoption, payer reimbursement, and annual prescription refills given the patch's daily use. Patch API is manufactured by Sanofi under contract, while finished patch manufacturing is handled by FAREVA. Beyond peanut allergy, DBV has earlier-stage programs using the same Viaskin platform for milk allergy and eosinophilic esophagitis, with the long-term goal of building a broad epicutaneous immunotherapy pipeline across multiple allergen targets.